New asthma injection shows promise in early trial

NCT ID NCT06441812

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests a new drug called SHR-1703, given as multiple injections under the skin, for people with eosinophilic asthma. The goal is to see if it is safe and helps control asthma over the long term. About 200 adults will take part, and researchers will monitor side effects, lung function, and asthma flare-ups for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR-1703 injection

What this could lead to

If successful, this could provide a new treatment option to better control eosinophilic asthma and reduce flare-ups.

What could go wrong

This is an early-phase trial with only 200 participants, so results may not apply to everyone. Side effects are still being studied, and the drug may not improve asthma control significantly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact